Pre-market hot trades in US stocks: Can-Fite BioPharma pre-market down 3.31%; TruGolf pre-market down 3.23%

Pre-market Hot Trades in US Stocks

Can-Fite is down 3.31% in pre-market trading. Based on recent key news:

1. On November 18, Can-Fite BioPharma announced that its drug Namodenoson received orphan drug designation from the US FDA and the European Medicines Agency, and was granted fast track designation for the treatment of hepatocellular carcinoma. This news drove the stock price up 51.27% in pre-market trading, but it subsequently fell due to market adjustments.

2. On November 18, the company is in the advanced stages of clinical trials, with its technology platform targeting a multi-billion dollar market, including treatments for cancer, liver disease, and inflammatory diseases. Its drug has shown good safety in clinical studies, attracting investor attention and leading to a surge in trading volume.

3. On November 19, D. Boral Capital maintained a target price of $11 per share for Can-Fite Biopharma, reflecting market confidence in its future development. The biopharmaceutical industry has been volatile recently and requires attention.

TruGolf is down 3.23% in pre-market trading. Based on recent key news:

1. On November 17, TruGolf released its third-quarter financial report, showing strong profit margins and an enhanced balance sheet, supporting its long-term growth strategy. Despite the good performance in the financial report, market concerns about its future growth may lead to a pre-market decline in stock price.

2. On November 17, TruGolf announced the ongoing development of its E6 APEX, LaunchBox, and the TruGolf Range platform, which will debut at the 2026 PGA Show, as well as progress in AI-driven analytics and the construction of its first "Golf Everywhere" franchise installation. These innovative initiatives may not have immediately boosted market confidence, leading to stock price fluctuations. The US stock market has seen increased volatility recently and requires attention.

Top Gainers in Pre-market Trading of US Stocks

Kazia Therapeutics is up 60.59% in pre-market trading. Based on recent news:

1. On November 18, Kazia Therapeutics announced progress in its PD-L1 protein resistance project, aimed at addressing the resistance mechanisms of current checkpoint inhibitors. Additionally, the company has made progress in its glioblastoma (GBM) project and plans to apply for an FDA Type C meeting after demonstrating strong overall survival signals in the paxalisib study. These positive R&D advancements have significantly boosted the stock price.

2. On November 18, Kazia Therapeutics disclosed that it received a notice from Nasdaq regarding non-compliance with minimum market value requirements for listing securities, requiring compliance by November 10, 2025. Despite this negative news, market optimism regarding its R&D progress continues to dominate stock price movements. The biopharmaceutical industry has performed strongly recently, with R&D advancements receiving significant attention Polestar Automotive UK PLC - CW 27, pre-market up 40.82%, no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Santech, pre-market up 32.21%, no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation